Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy
about
Exploiting tumor epigenetics to improve oncolytic virotherapyOncolytic viruses as therapeutic cancer vaccinesThunder and lightning: immunotherapy and oncolytic viruses collidePancreatic cancer from bench to bedside: molecular pathways and treatment optionsViro-immune therapy: A new strategy for treatment of pancreatic cancerPromising oncolytic agents for metastatic breast cancer treatmentOncolytic viruses as anticancer vaccinesReciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesPermissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activityHandling of the cotton rat in studies for the pre-clinical evaluation of oncolytic viruses.Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo.Designing Herpes Viruses as Oncolytics.Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity.Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancerA polysaccharide isolated from Agaricus blazei Murill (ABP-AW1) as a potential Th1 immunity-stimulating adjuvant.Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments.Oncolytic vaccines.Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.Enhanced efficacy with azacytidine and oncolytic BHV-1 in a tolerized cotton rat model of breast adenocarcinoma.Oncolytic Immunotherapy for Treatment of Cancer.Immune System, Friend or Foe of Oncolytic Virotherapy?Oncolytic viruses: adenoviruses.Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity.Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models.Vaccine adjuvant ginsenoside Rg1 enhances immune responses against hepatitis B surface antigen in mice.Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer.Carnitine transport and fatty acid oxidation.Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis.Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.Oncolytic Virotherapy and the Tumor Microenvironment.Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages.
P2860
Q21131237-F3E85264-44B7-4FCB-B7A9-ADC44FE5490EQ21245758-18D32EF5-035A-4ACF-8878-ED3C0E7F53FCQ24597894-CB270829-54A3-457D-B63D-8441B6D02D8CQ26747524-65ED2615-AD30-4FB2-854C-A47DB0FBAFBEQ26774641-0632F2FB-86A8-4C46-B08D-5A32AD99588BQ26830620-0E4B6C47-920E-4D1B-AA4B-F4B3E07BCB82Q27025600-F61C41D8-5A45-458D-BBEF-ABCFA9CC1B13Q30300159-C5851CA6-AE78-4710-90B2-88867D9CDE7CQ33679505-ED10EB21-A069-40EC-B43C-873643CAC5BAQ33743847-94AC187B-7807-4DCC-95EB-E2E1FAA76B61Q35161325-9625042F-08C0-4E44-828F-417849CAFB7EQ35740932-ECE053C8-46CE-478D-BE38-6703944F0B26Q35750051-20C42C2C-05AC-4DD3-8FB3-878C823BE48EQ36142487-7D4656DD-3F29-415D-AF9A-5B9E0A7BD0E6Q36220618-8DB53F9E-8A1C-4D2A-BD29-CE5EB449577DQ36664245-F64A31BB-EB0A-4323-8A93-6649D3A6EBE9Q36700481-B0907EF5-003E-4F73-BA43-8E16736240E3Q37225501-D5F1DABA-7CC4-4B3B-B809-EF00063DAD82Q37229386-CD9DE92D-D2AF-4BB0-86F2-948F91D68B46Q37417271-03BE085F-D13F-4DA2-876F-B1F1D3E1201AQ37707676-75536A64-5A6D-4CCB-9E78-EBFC3CDA6EA7Q38025696-EA32574F-B457-4DCF-A6FE-D95244E8F26FQ38119845-570BCE1C-63A7-4DFF-B390-245A40A8BF71Q38152474-3576B2A2-D7D9-4D2A-AA23-4F7F34EE6603Q38194135-195EAA54-8B29-4D9E-9827-71CBFBE522ADQ38223419-28063FF0-B064-4837-BCA7-96C9DF0DA841Q38648891-A0D9DD4A-25FB-4004-B1D0-CA821D6A49C2Q38845195-9AE359B2-807D-4CC9-8544-CC1C3CC957EAQ38848223-862A1509-26B2-4F6F-BE91-76779D287EFBQ39355854-32381841-BE80-4EB9-8CD6-8E942388BAAEQ39432063-3450C714-CAA3-494B-9DE0-6F760D59635BQ40063602-14C861D0-6058-48A8-BBAF-96A8DD3F68BCQ40064004-8BCEDE25-35D8-481A-94FC-6E2D52159103Q40791130-A44A58A5-E240-4B72-91F6-F45F8CE76EA8Q40907752-080059F1-4813-4CAB-8128-EBF728C861BDQ41633875-A0D8F219-B85F-4E27-8F41-04BFE97C0167Q42280873-F02E256E-1E2C-4069-880A-5CBA3A2E1CCFQ47365404-92B25616-30A7-42ED-8962-E53AF86471F4Q47560690-507B1EB9-9CD9-479B-8865-CCCC59E0C5BDQ53688637-289BD5AF-FB6B-4AB1-8F63-98EFDA9AF02F
P2860
Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy
@ast
Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy
@en
Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy
@nl
type
label
Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy
@ast
Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy
@en
Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy
@nl
prefLabel
Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy
@ast
Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy
@en
Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy
@nl
P2093
P2860
P356
P1433
P1476
Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy
@en
P2093
Brian D Lichty
Jeanette E Boudreau
Kyle Stephenson
Paul T Sobol
Yonghong Wan
P2860
P304
P356
10.1038/MT.2010.264
P577
2010-11-30T00:00:00Z